ExpreS2ion will participate in key industry and investor events
Hørsholm, Denmark, May 24, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include an Oncology webinar (May 31) and presentation of Q1 2022 results (June 9), both hosted by H.C. Andersen Capital, the ECI Vaccine Technology VIII conference (June 12-17) and the world’s largest biotech conference, the BIO International Convention (June 13-16).
By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS2 technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below.
Oncology webinar hosted by H.C. Andersen Capital, May 31 at 10:00 CET
Virtual
ExpreS2ion VP of Preclinical Development Mette Thorn and CFO Keith Alexander will provide an update on ExpreS2ion’s HER2+ therapeutic breast cancer vaccine program and answer participants’ questions. More information and registration can be found on the H.C. Andersen Capital events website.
Presentation of Q1 2022 results hosted by H.C. Andersen Capital, June 9 at 13:00 CET
Virtual
ExpreS2ion CEO Bent U. Frandsen will discuss the Q1 2022 results and answer investors’ questions. More information and registration can be found on the H.C. Andersen Capital events website.
ECI Vaccine Technology VIII Conference, June 12-17
Sitges, Spain
Meet our scientists at the leading conference focused on the discovery, development and manufacture of vaccines, hosted by ECI. More information and registration can be found on the ECI website.
BIO International Convention, June 13-16
San Diego, CA, USA
Meet ExpreS2ion CEO, Bent Frandsen, at the largest global biotechnology industry event. More information and registration can be found on the BIO website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.